Asthma causes difficulty breathing, coughing, and shortness of breath in about 25 million Americans, costing the US at least $80 billion annually and resulting in more than 1.5 million visits to the emergency department, half a million hospitalizations, and 3500 deaths each year. During an asthma attack, or exacerbation, affected individuals have only two possible effective treatments: corticosteroids or beta-adrenergic agents. Neither are uniformly effective or address the underlying cause of the exacerbation. Patients quickly develop a tolerance to beta adrenergic drugs, while corticosteroids are slow to act. Preventing an exacerbation is only possible through daily inhaled corticosteroids where adherence is poor or very expensive antibody therapies, which also cannot treat asthma exacerbations.
Wenzel, S. E., Tyurina, Y. Y., Zhao, J., St. Croix, C. M., Dar, H. H., Mao, G., Tyurin, V. A., Anthonymuthu, T. S., Kapralov, A. A., Amoscato, A. A., Mikulska-Ruminska, K., Shrivastava, I. H., Kenny, E. M., Yang, Q., Rosenbaum, J. C., Sparvero, L. J., Emlet, D. R., Wen, X., Minami, Y., … Kagan, V. E. (2017). PEBP1 Wardens Ferroptosis by Enabling Lipoxygenase Generation of Lipid Death Signals. Cell, 171(3), 628-641.e26. https://doi.org/10.1016/j.cell.2017.09.044